Biblio
Export 1129 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is T [Clear All Filters]
“Mendelian Randomization of Blood Metabolites Suggests Circulating Glutamine Protects Against Late-Onset Alzheimer's Disease.”, J Alzheimers Dis, vol. 98, no. 3, pp. 1069-1078, 2024.
, “Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. s1, pp. S285-S298, 2024.
, “Pharmacologic and Nutritional Interventions for Early Alzheimer's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.”, J Alzheimers Dis, vol. 99, no. 4, pp. 1173-1186, 2024.
, “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
, “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
, “The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug.”, J Alzheimers Dis, vol. 99, no. 1, pp. 161-175, 2024.
, “RNA Analysis of Circulating Leukocytes in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1673-1683, 2024.
, “Serial Cerebrospinal Fluid Sampling Reveals Trajectories of Potential Synaptic Biomarkers in Early Stages of Alzheimer's Disease.”, J Alzheimers Dis, vol. 100, no. s1, pp. S103-S114, 2024.
, “Small RNA Profiles of Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S235-S248, 2024.
, “Small RNA Profiles of Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S235-S248, 2024.
, “Small Vessel Disease Burden Predicts Incident Dementia and Poor Functional Outcome in Independent Outpatients.”, J Alzheimers Dis, vol. 101, no. 3, pp. 751-760, 2024.
, “Social Activity and Cognitive Decline in Older Residents of Long-Term Care Facilities: A Cohort Study.”, J Alzheimers Dis, vol. 98, no. 2, pp. 433-443, 2024.
, “Space-Like Irradiation Exacerbated Cognitive Deficits and Amyloid Pathology in CRND8 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 100, no. s1, pp. S327-S339, 2024.
, “Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals.”, J Alzheimers Dis, vol. 100, no. 1, pp. 193-205, 2024.
, “A systematic review of lifestyle-based interventions for managing Alzheimer's disease: Insights from randomized controlled trials.”, J Alzheimers Dis, vol. 102, no. 4, pp. 943-966, 2024.
, “Targeting Caspases 3/6 and Cathepsins L/B May Decrease Laminopathy-Induced Apoptosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. 1, pp. 211-221, 2024.
, “There are dementia patients in Gaza too.”, J Alzheimers Dis, vol. 102, no. 2, pp. 317-320, 2024.
, “Transcriptomic Profiling Reveals Neuroinflammation in the Corpus Callosum of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1421-1433, 2024.
, “Unveiling New Strategies Facilitating the Implementation of Artificial Intelligence in Neuroimaging for the Early Detection of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 1-20, 2024.
, “Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 241-260, 2023.
, “Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2.”, J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
, “Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2.”, J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
, “Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.”, J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
, “Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial.”, J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
, “Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1121-1132, 2023.
,